Nasdaq:US$18.31 (-0.90) | HKEX:HK$28.00 (-1.35) | AIM:£2.68 (-0.05)
News & Presentations
Previous Article   |   Next Article
Presentations, Scientific Publications | 1 Jun 2012

ASCO 2012: First-in-human phase I study of a selective VEGFR/FGFR dual inhibitor sulfatinib in patients with advanced solid tumors